Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction
BACKGROUND: Half of all patients with chronic heart failure (CHF) have preserved ejection fraction (CHF-nEF). The drug’s use effective for treatment of CHF with reduced ejection fraction (CHF-nFV) reduces the hospitalization incidence but does not affect the cardiovascular incidence or overall morta...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2024-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13028 |
| _version_ | 1797255072593215488 |
|---|---|
| author | T. S. Sveklina S. B. Shustov S. N. Kolyubayeva A. N. Kuchmin V. A. Kozlov E. V. Smirnova A. V. Zharkov |
| author_facet | T. S. Sveklina S. B. Shustov S. N. Kolyubayeva A. N. Kuchmin V. A. Kozlov E. V. Smirnova A. V. Zharkov |
| author_sort | T. S. Sveklina |
| collection | DOAJ |
| description | BACKGROUND: Half of all patients with chronic heart failure (CHF) have preserved ejection fraction (CHF-nEF). The drug’s use effective for treatment of CHF with reduced ejection fraction (CHF-nFV) reduces the hospitalization incidence but does not affect the cardiovascular incidence or overall mortality in patients with CHF-nFV. Finding differences between CSN-SFV and CSN-nFV biomarkers is a pressing scientific problem.AIM: To study the metabolic disorders biomarkers intergenic relationships, myocardial damage, and to evaluate their role in the CHF development in patients with DM2.MATERIALS AND METHODS: We studied the lipid and carbohydrate metabolism disorder genes polymorphisms frequencies in patients with CHF-CFV and DM2 (48 patients), CHF-NFV and DM2 (46) and patients with metabolic syndrome (MS) without CHF (68), mean age of patients was 69,7±5,3 yo. DNA was isolated from venous blood according to the manufacturer’s methodology. Gene polymorphisms were determined by real time PCR. The studied polymorphisms correlations with clinical and laboratory data and associations between clinical and laboratory tests were identified by regression analysis.RESULTS: In the control group, PPARG, APOC3 C3238G rs5128, LIPC -250 G>A rs2070895, APOA1 G-75A rs670, FABP2 Ala54Thr G>A rs1799883, ADRB2 5318 C>G rs1042714 genes polymorphisms, along with co-dependent ADRB3, FTO, FABP2 genes polymorphic form a gene network regulating plasma concentrations of LDL, uric acid and CAD. Gene polymorphisms have been found to be associated with clinical and/or laboratory parameters in patients with CHF-CFV: PPARGC1AGly482Ser G>A rs8192678 with CAD; PPARGT-2821C rs12497191 with glycated hemoglobin level; FTO A>T rs9939609 (α-ketoglutarate dependent dioxygenase gene) with waist circumference; LEPR A>G rs1137101 (leptin receptor gene) with MAP. The following polymorphisms were found to be associated in patients with CHF-nFV: LIPC-250 G>A rs2070895 (liver triglyceride lipase gene) with MAP; PPARGC1A Gly482Ser G>A rs8192678 with MAP; FTO A>T rs9939609 with waist volume.CONCLUSIONS: From the study results, it is evident that patients with DM2 having CHF with different PV differ significantly among themselves by the presence of polymorphic genes prone to network interactions. The greatest number of such interactions is observed in the group of CHF-sFV, which determines a more complex course of this variant of CHF than in patients with CHF-nFV. |
| first_indexed | 2024-04-24T22:00:02Z |
| format | Article |
| id | doaj.art-798f78781ea749169fbb80e4e3481e66 |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:00:02Z |
| publishDate | 2024-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-798f78781ea749169fbb80e4e3481e662024-03-20T11:48:05ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782024-03-01271152410.14341/DM1302811048Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fractionT. S. Sveklina0S. B. Shustov1S. N. Kolyubayeva2A. N. Kuchmin3V. A. Kozlov4E. V. Smirnova5A. V. Zharkov6Military Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovMilitary Medical Academy named after S.M. KirovChuvash State University named after I.N. UlyanovMilitary Medical Academy named after S.M. KirovNorth-Western State Medical University named after I.I. MechnikovBACKGROUND: Half of all patients with chronic heart failure (CHF) have preserved ejection fraction (CHF-nEF). The drug’s use effective for treatment of CHF with reduced ejection fraction (CHF-nFV) reduces the hospitalization incidence but does not affect the cardiovascular incidence or overall mortality in patients with CHF-nFV. Finding differences between CSN-SFV and CSN-nFV biomarkers is a pressing scientific problem.AIM: To study the metabolic disorders biomarkers intergenic relationships, myocardial damage, and to evaluate their role in the CHF development in patients with DM2.MATERIALS AND METHODS: We studied the lipid and carbohydrate metabolism disorder genes polymorphisms frequencies in patients with CHF-CFV and DM2 (48 patients), CHF-NFV and DM2 (46) and patients with metabolic syndrome (MS) without CHF (68), mean age of patients was 69,7±5,3 yo. DNA was isolated from venous blood according to the manufacturer’s methodology. Gene polymorphisms were determined by real time PCR. The studied polymorphisms correlations with clinical and laboratory data and associations between clinical and laboratory tests were identified by regression analysis.RESULTS: In the control group, PPARG, APOC3 C3238G rs5128, LIPC -250 G>A rs2070895, APOA1 G-75A rs670, FABP2 Ala54Thr G>A rs1799883, ADRB2 5318 C>G rs1042714 genes polymorphisms, along with co-dependent ADRB3, FTO, FABP2 genes polymorphic form a gene network regulating plasma concentrations of LDL, uric acid and CAD. Gene polymorphisms have been found to be associated with clinical and/or laboratory parameters in patients with CHF-CFV: PPARGC1AGly482Ser G>A rs8192678 with CAD; PPARGT-2821C rs12497191 with glycated hemoglobin level; FTO A>T rs9939609 (α-ketoglutarate dependent dioxygenase gene) with waist circumference; LEPR A>G rs1137101 (leptin receptor gene) with MAP. The following polymorphisms were found to be associated in patients with CHF-nFV: LIPC-250 G>A rs2070895 (liver triglyceride lipase gene) with MAP; PPARGC1A Gly482Ser G>A rs8192678 with MAP; FTO A>T rs9939609 with waist volume.CONCLUSIONS: From the study results, it is evident that patients with DM2 having CHF with different PV differ significantly among themselves by the presence of polymorphic genes prone to network interactions. The greatest number of such interactions is observed in the group of CHF-sFV, which determines a more complex course of this variant of CHF than in patients with CHF-nFV.https://www.dia-endojournals.ru/jour/article/view/13028congestive heart failure with preserved ejection fractiontype 2 diabetes mellituspolymorphismrs769452rs5128rs662rs328rs2070895rs8192678rs773267rs1801282rs3856806rs1801282rs12497191rs1801282rs9939609rs670rs1799883rs1137101rs1042714rs1042713rs4994 |
| spellingShingle | T. S. Sveklina S. B. Shustov S. N. Kolyubayeva A. N. Kuchmin V. A. Kozlov E. V. Smirnova A. V. Zharkov Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction Сахарный диабет congestive heart failure with preserved ejection fraction type 2 diabetes mellitus polymorphism rs769452 rs5128 rs662 rs328 rs2070895 rs8192678 rs773267 rs1801282 rs3856806 rs1801282 rs12497191 rs1801282 rs9939609 rs670 rs1799883 rs1137101 rs1042714 rs1042713 rs4994 |
| title | Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction |
| title_full | Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction |
| title_fullStr | Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction |
| title_full_unstemmed | Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction |
| title_short | Metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction |
| title_sort | metabolic biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction |
| topic | congestive heart failure with preserved ejection fraction type 2 diabetes mellitus polymorphism rs769452 rs5128 rs662 rs328 rs2070895 rs8192678 rs773267 rs1801282 rs3856806 rs1801282 rs12497191 rs1801282 rs9939609 rs670 rs1799883 rs1137101 rs1042714 rs1042713 rs4994 |
| url | https://www.dia-endojournals.ru/jour/article/view/13028 |
| work_keys_str_mv | AT tssveklina metabolicbiomarkersinpatientswithtype2diabetesmellitusandheartfailurewithpreservedejectionfraction AT sbshustov metabolicbiomarkersinpatientswithtype2diabetesmellitusandheartfailurewithpreservedejectionfraction AT snkolyubayeva metabolicbiomarkersinpatientswithtype2diabetesmellitusandheartfailurewithpreservedejectionfraction AT ankuchmin metabolicbiomarkersinpatientswithtype2diabetesmellitusandheartfailurewithpreservedejectionfraction AT vakozlov metabolicbiomarkersinpatientswithtype2diabetesmellitusandheartfailurewithpreservedejectionfraction AT evsmirnova metabolicbiomarkersinpatientswithtype2diabetesmellitusandheartfailurewithpreservedejectionfraction AT avzharkov metabolicbiomarkersinpatientswithtype2diabetesmellitusandheartfailurewithpreservedejectionfraction |